Trial Profile

Phase 2a trial evaluating RAP-219 in patients with peripheral neuropathic pain

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Mar 2025 According to Rapport Therapeutics media release, the data from this study will be presented at the 2025 American Academy of Neurology Annual Meeting.
11 Mar 2025 According to Rapport Therapeutics media release, The FDA requested additional information and protocol design amendments. The Company is now finalizing its trial plans with a goal of advancing work in this area of high unmet need as quickly as possible.
07 Nov 2024 According to Rapport Therapeutics media release, the company was recently notified by the FDA that the IND submitted by the Company for the initiation of this trial was placed on clinical hold.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com